The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scienfific findings into the clinic. WON Members study novel pathways by which hormones and growth factors regulate growth and metastasis of women's cancers;identify potential new therapeufic targets or prognostic indicators for response or resistance to therapy;and perform clinical trials to test efficacy of therapeutic agents in treating these cancers. Program leadership has organized WON around three research themes: (1) steroid hormone action and steroid-dependent cancers;(2) growth factor and cytokine promotion of tumor development and metastasis;and (3) invesfigator-initiated clinical research and development of novel clinical research tools. Professor of Medicine and Physiology Margaret A. Shupnik, PhD, and Professor of Medicine Paula M. Fracasso, MD, PhD, lead the Program. Dr. Shupnik has expertise in molecular endocrinology and estrogen receptor action, and Dr. Fracasso is an experienced clinical trialist in women's oncology. The Program represents a wide variety of expertise: 22 Members from nine departments in the schools of Medicine and of Engineering, and six Associate Members. With critical CCSG help, seven WON Members have joined the University of Virginia (UVA) since the last renewal, and two Members have been retained. The following areas of support have enabled the success of WON research initiatives, which have become increasingly cancer focused and interactive: funding for faculty recruitment and retention;funding for informafion exchange forums, such as the CC Seminar Series, WON research meetings, and the Program Retreat;Cancer Center Pilot Project Funds;and support from the UVA Cancer Center Shared Resources. Total extramural funding for the Program exceeds $10.5 million, including nearly $5 million from the Nafional Cancer Institute (NCI). Over the past five years, WON Members have published 317 Program-relevant papers of which 29% were inter-Programmatic and 21% were intra-Programmatic.

Public Health Relevance

; The goal of the Women's Oncology Program (WON) is: (1) to accelerate the pace and expand the range of fundamental discovery research about women's cancers and (2) to facilitate the translation of new scientific findings into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA044579-21
Application #
8231125
Study Section
Subcommittee G - Education (NCI)
Project Start
2012-02-01
Project End
2017-01-31
Budget Start
2012-06-05
Budget End
2013-01-31
Support Year
21
Fiscal Year
2012
Total Cost
$28,732
Indirect Cost
$10,509
Name
University of Virginia
Department
Type
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Kulling, Paige M; Olson, Kristine C; Hamele, Cait E et al. (2018) Dysregulation of the IFN-?-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLoS One 13:e0193429
Grant, Margaret J; Loftus, Matthew S; Stoja, Aiola P et al. (2018) Superresolution microscopy reveals structural mechanisms driving the nanoarchitecture of a viral chromatin tether. Proc Natl Acad Sci U S A 115:4992-4997
Knapp, Kiley A; Pires, Eusebio S; Adair, Sara J et al. (2018) Evaluation of SAS1B as a target for antibody-drug conjugate therapy in the treatment of pancreatic cancer. Oncotarget 9:8972-8984
Kedzierska, Katarzyna Z; Gerber, Livia; Cagnazzi, Daniele et al. (2018) SONiCS: PCR stutter noise correction in genome-scale microsatellites. Bioinformatics 34:4115-4117
Zhang, Xuewei; Kitatani, Kazuyuki; Toyoshima, Masafumi et al. (2018) Ceramide Nanoliposomes as a MLKL-Dependent, Necroptosis-Inducing, Chemotherapeutic Reagent in Ovarian Cancer. Mol Cancer Ther 17:50-59
Cruickshanks, Nichola; Zhang, Ying; Hine, Sarah et al. (2018) Discovery and Therapeutic Exploitation of Mechanisms of Resistance to MET Inhibitors in Glioblastoma. Clin Cancer Res :
Balogh, Kristen N; Templeton, Dennis J; Cross, Janet V (2018) Macrophage Migration Inhibitory Factor protects cancer cells from immunogenic cell death and impairs anti-tumor immune responses. PLoS One 13:e0197702
Gonzalez, Phillippe P; Kim, Jungeun; Galvao, Rui Pedro et al. (2018) p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Glia 66:999-1015
Rodriguez, Anthony B; Peske, J David; Engelhard, Victor H (2018) Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. Methods Mol Biol 1845:241-257
Stowman, Anne M; Hickman, Alexandra W; Mauldin, Ileana S et al. (2018) Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures. Melanoma Res 28:237-245

Showing the most recent 10 out of 539 publications